Pharmacokinetic, Safety and Tolerability Study of SPARC1028

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of solid tumor in advanced stage which taxane-based therapy is a rational treatment option. * Age ≥18 years * ECOG Performance Status ≤ 1. * Estimated life expectancy of at least 12-weeks; Exclusion Criteria: * Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer * Known hypersensitivity to the study drugs * Treatment with any anti-cancer agents within 28 days of study entry * Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy